Study study type PathologyT1T0Patientssample sizesROB Results

mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population

versus ipilimumab alone
nivolumab alone
CheckMate 067 (N vs I ; all population), 2015
  NCT01844505
RCTmML - L1 - all populationnivolumabipilimumabwith previously untreated, unresectable or metastatic histologically confirmed stage III or IV melanoma.316 / 315low
conclusif
  • demonstrated 37 % decrease in deaths (OS) (PE)
  • demonstrated 43 % decrease in progression or deaths (PFS) (PE)
  • suggested 37 % decrease in deaths (OS) (extension)
  • suggested 47 % decrease in PFS (extension)
  • more...
nivolumab plus ipilimumab
CheckMate 067 (NI vs I ; all population), 2015
  NCT01844505
RCTmML - L1 - all populationnivolumab plus ipilimumabipilimumabpatients with previously untreated, unresectable or metastatic histologically confirmed stage III or IV melanoma.314 / 315low
conclusif
  • demonstrated 45 % decrease in deaths (OS) (PE)
  • demonstrated 58 % decrease in progression or deaths (PFS) (PE)
  • suggested 48 % decrease in deaths (OS) (extension)
  • suggested 58 % decrease in PFS (extension)
  • more...
CheckMate 069 (all population), 2015
  NCT01927419
RCTmML - L1 - all populationnivolumab and ipilimumabipilimumabunresectable, previously untreated stage III or IV melanoma with measurable disease, with BRAF Wild-Type Tumors and BRAF mutant95 / 47low
conclusif
  • demonstrated 62 % decrease in progression or deaths (PFS) (PE)
  • suggested 64 % decrease in PFS (extension)
  • demonstrated 14.1-fold increase in objective responses (ORR) (PE)
versus ipilimumab followed by nivolumab
nivolumab followed by ipilimumab
CheckMate 064, 2016
  NCT01783938
RCTmML - L1 - all populationnivolumab followed by ipilimumabipilimumab followed by nivolumabunresectable stage III or stage IV melanoma, and were previously untreated or had progressed after no more than one previous systemic therapy68 / 70high
suggested
  • suggested 52 % decrease in deaths (OS)
versus nivolumab alone
nivolumab plus ipilimumab
CheckMate 067 (NI vs N) EXPLORATORY, 2015
  NCT01844505
RCTmML - L1 - all populationnivolumab plus ipilimumabnivolumabpatients with previously untreated, unresectable or metastatic histologically confirmed stage III or IV melanoma.314 / 316low
inconclusive
  • suggested 35 % decrease in deaths (OS)
  • suggested 21 % decrease in PFS (extension)
  • suggested 26 % decrease in progression or deaths (PFS)
relatlimab plus nivolumab
RELATIVITY-047 unpublished
  NCT03470922
RCTmML - L1 - all populationrelatlimab plus nivolumabnivolumabpatient (>= 12yr) with previously untreated, unresectable or metastatic disease melanoma-/-NA
suggested
  • suggested 25 % decrease in progression or deaths (PFS) (PE)
versus Standard of Care (SoC)
tremelimumab
A3671009, 2013
  NCT00257205
RCTmML - L1 - all populationtremelimumabphysician's choice of standard-of-care chemotherapy (temozolomide or dacarbazine)patients with treatment-naive, unresectable stage IIic or IV melanoma328 / 327some concern
inconclusive
  • inconclusive 12 % decrease in deaths (OS) (PE)
INCONCLUSIVE FOR OS